Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $125
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sanofi (OtherSNYNF) and Viking Therapeutics (VKTX)
Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 and VK2735 Clinical Data
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Stifel Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $95
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows Promising Weight Loss and Safety Profile
Viking Therapeutics Initiated at Overweight by JP Morgan
Viking Therapeutics Analyst Ratings
J.P. Morgan Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $80
No Data
No Data